You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
View important safety information regarding the commercial TAVI device used in the trial by visiting the link below.
The purpose of the EXPAND TAVR II Pivotal Trial is to explore the treatment of moderate aortic stenosis (AS) with early transcatheter aortic valve implantation (TAVI) before AS becomes severe. Early treatment of AS may help preserve cardiac function, prevent or slow further deterioration in cardiac function, and prevent death in some patients.
~650 randomized subjects
~100 centers
Australia, Canada, Europe, Israel, Japan, New Zealand, and United States
10 years of follow-up
Multicenter, international, prospective, randomized
For details about locations for the EXPAND TAVR II Pivotal Trial, visit the clinicaltrials.gov trial website below.
Visit clinicaltrials.gov for more information about the EXPAND TAVR II Pivotal Trial.
Use identifier number NCT05149755 to see details on the EXPAND TAVR II Pivotal Trial.
To learn more about TAVI and the procedure, please visit the link below.
Inquiries about referring patients?
Email rs.expandii-emea@medtronic.com
Please visit clinicaltrials.gov for a list of patient selection criteria.
Patients presenting with LVEF < 50%, AVA of ≤ 1.0 cm2, and mean gradient ≥ 20 mmHg and < 40 mmHg at rest may undergo low-dose DSE to assess if subject has moderate AS versus low-flow, low-gradient severe AS.
Age < 75 years in France
More details available in clinical investigational plan from Medtronic.
** CE mark pending, not available for commercial distribution in the EU.
Strange G, Stewart S, Celermajer D, et al. Poor Long-Term Survival in Patients With Moderate Aortic Stenosis. J Am Coll Cardiol. October 15, 2019;74(15):1851-1863.
See the CoreValve™ Evolut™ R, the CoreValve™ Evolut™ PRO and the Evolut™ PRO+ device manuals for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.
For applicable products, consult instructions for use on manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.
The commercial name of the Evolut™ R device is Medtronic CoreValve™ Evolut™ R System, the commercial name of the Evolut™ PRO device is Medtronic CoreValve™ Evolut™ PRO System and the commercial name of the Evolut™ PRO+ device is Medtronic Evolut™ PRO+ System.
© 2023 Medtronic. All rights reserved, Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic™.* Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.